Trial Profile

A Phase 1 Study of ZN-c3 as a Single Agent in Subjects With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azenosertib (Primary) ; Pembrolizumab; Talazoparib
Indications Carcinoma; Solid tumours; Uterine cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors K-Group Beta; Zentalis Pharmaceuticals

Most Recent Events

26 Oct 2025 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025
13 Oct 2025 According to Zentalis Pharmaceuticals media release, results of this trial will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025 at the Hynes Convention Center in Boston, Massachusetts.
29 Jan 2025 Results published in the Zentalis Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com